Previous 10 | Next 10 |
Fremont, CA - ( NewMediaWire ) - May 12, 2022 - ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase agreements with certain institutional investors for the issuance and sale of 2,000,000 sh...
Fremont, CA - ( NewMediaWire ) - May 10, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the first subject began treatment at the Cheng Hsin General Ho...
New Process Improves Quality and Lowers Cost Fremont, CA - ( NewMediaWire ) - May 05, 2022 - ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vi...
New Process Improves Quality and Lowers Cost Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology...
ABVC Biopharma (NASDAQ:ABVC) has announced that BioKey, a wholly-owned subsidiary of the Co., has entered into a $3M clinical services contract with NeuCen BioMed. The contract will guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. F...
Fremont, CA - ( NewMediaWire ) - May 03, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the company based in Frem...
Fremont, CA - ( NewMediaWire ) - April 28, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the...
FREMONT, CA - ( NewMediaWire ) - April 26, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the principal investigators of the Phase II clinical study o...
ABVC BioPharma press release (NASDAQ:ABVC): FY net loss of $12.03M Revenue of $355.79M (-26.3% Y/Y). For further details see: ABVC BioPharma reports FY results
Fremont, CA - ( NewMediaWire ) - March 31, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...